Bridgebio Pharma, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersPalo Alto, CA
SAM.gov UEILSA5MDHDB961
BridgeBio is a pharmaceutical company that develops investigational medicines for rare genetic and metabolic diseases. The company's pipeline includes candidates such as acoramidis for transthyretin amyloidosis, BBP-418 for limb-girdle muscular dystrophy, encaleret for hypocalcemia, infigratinib for achondroplasia, and BBP-812 for Canavan disease, with three products having received FDA approvals.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Bridgebio Pharma, INC. | Palo Alto | CA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.